Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$155.86M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.71M
EBITDA Margin
-3676.90%
TTM Avg
-2033.97%
3Y Avg
-1569.70%
5Y Avg
-1569.70%
Market Cap
$153.61M
EBITDA Margin
4.91%
TTM Avg
4.91%
3Y Avg
4.91%
5Y Avg
4.91%
Market Cap
$152.16M
EBITDA Margin
-48812.58%
TTM Avg
-48812.58%
3Y Avg
-48812.58%
5Y Avg
-48812.58%
Market Cap
$150.66M
EBITDA Margin
-47.00%
TTM Avg
-68.63%
3Y Avg
-61.93%
5Y Avg
-48.63%
Market Cap
$163.00M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$147.97M
EBITDA Margin
-0.19%
TTM Avg
-1.66%
3Y Avg
-11.02%
5Y Avg
-42.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $155.86M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.71M | -3676.90% | -2033.97% | -1569.70% | -1569.70% |
| Inogen, Inc. (INGN)vs › | $157.47M | -2.74% | -4.58% | -13.60% | -7.28% |
| Minerva Neurosciences, Inc. (NERV)vs › | $153.61M | 4.91% | 4.91% | 4.91% | 4.91% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -48812.58% | -48812.58% | -48812.58% | -48812.58% |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.05M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $150.66M | -47.00% | -68.63% | -61.93% | -48.63% |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | -416.41% | -228.13% | -163.44% | -116.60% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -0.19% | -1.66% | -11.02% | -42.72% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $146.71M | N/A | N/A | N/A | N/A |
Gross Margin
N/A
EBITDA Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
